CytomX Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
CytomX Therapeutics, Inc. (CTMX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $2.80 million for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-07.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2016-03-07
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2015 was $2.80M, a 582.93% increase from fiscal 2014.
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2014 was $410.00K, a 52.99% increase from fiscal 2013.
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2013 was $268.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|
| 2015-12-31 | $2.80M 10-K · filed 2016-03-07 |
| 2014-12-31 | $410.00K 10-K · filed 2016-03-07 |
| 2013-12-31 | $268.00K 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |